Adverse effects are mainly related to its antimuscarinic effects. Common adverse drug reactions (≥1% of people) include: dry mouth and/or throat irritation. Rarely (<0.1% of patients) treatment is associated with: urinary retention, constipation, acute angle closure glaucoma, palpitations (notably supraventricular tachycardia and atrial fibrillation) and allergy (rash, angioedema, anaphylaxis). A 2006 review found the increase in bronchospasm was small and did not reach statistical significance. Data regarding some serious side effects is mixed as of 2020. In September 2008 a review found that<unk>  and another member of its class ipratropium may be linked to increased risk of heart attacks, stroke and cardiovascular death. The US FDA reviewed the concern and concluded in 2010 that this association was not supported. A 2011 review of the<unk>  mist inhaler (Respimat); however, still found an associated with an increase in all cause mortality in people with COPD.
Tiotropium bromide
Fluticasone/salmeterol
Mometasone/formoterol
Beclometasone/formoterol
Fluticasone furoate
Fluticasone propionate
Theophylline
Roflumilast